熊去氧胆酸预防腹腔镜袖状胃切除术后胆石症:大西洋加拿大视角
本研究回顾性分析2009至2019年两中心751例腹腔镜袖状胃切除患者,其中461例纳入分析(UDCA组303例,非UDCA组158例)。UDCA组ERCP率显著低于非UDCA组(0.3% vs 2.5%,p=0.031),需干预的胆石症发生率也显著降低(8.9% vs 15.8%,p=0.022),但胆囊切除率差异无统计学意义(8.3% vs 13.9%,p=0.056)。结论支持ASMBS 2019指南推荐LSG术后使用UDCA预防胆石症。
要点
- LSG术后常规UDCA 250mg每日两次口服6个月可显著降低ERCP率。
- UDCA组需干预的胆石症发生率显著低于非UDCA组。
- UDCA主要依从性障碍为费用(45.4%)和恶心(18.1%)。
核心结论
- LSG术后常规使用UDCA可显著降低ERCP率及需干预的胆石症发生率,支持ASMBS 2019指南推荐。
研究设计与样本
- 回顾性病历审查,纳入2009至2019年大西洋加拿大两个三级中心行LSG的患者,最终分析461例(UDCA组303例,非UDCA组158例)。
主要发现
- 胆囊切除率在UDCA组与非UDCA组间无显著差异(8.3% vs 13.9%,p=0.056)。
- ERCP率在UDCA组显著低于非UDCA组(0.3% vs 2.5%,p=0.031)。
- 需干预的胆石症发生率在UDCA组显著低于非UDCA组(8.9% vs 15.8%,p=0.022)。
- UDCA依从性障碍主要为费用(45.4%)和恶心(18.1%)。
关键数值与推荐
- ASMBS 2019指南推荐LSG术后使用UDCA 6个月。
- 本研究UDCA方案为250mg口服每日两次,持续6个月。
临床怎么用
- 对LSG术后胆囊完整患者可考虑常规使用UDCA 250mg每日两次口服6个月以预防胆石症。
- 需关注UDCA的费用和恶心等副作用对依从性的影响。
局限性
- 回顾性研究设计,可能存在选择偏倚和信息偏倚。
- 样本来自两个中心,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prophylactic ursodeoxycholic acid (UDCA) may be beneficial in reducing gallstone disease after bariatric surgery. The American Society for Metabolic and Bariatric Surgery (ASMBS) 2019 guidelines recommend a 6-month course of UDCA for patients undergoing laparoscopic sleeve gastrectomy (LSG). This has not been adopted broadly. This study intends to assess the effect of routine UDCA administration following LSG on symptomatic gallstone disease. METHODS: We performed a retrospective chart review of patients who underwent LSG, between 2009 and 2019, at two tertiary care centers in Atlantic Canada. At one center, UDCA 250 mg oral twice daily was routinely prescribed following LSG for 6 months to patients with an intact gallbladder. At the other center, UDCA was not prescribed. Primary and secondary outcomes were cholecystectomy and endoscopic retrograde cholangiopancreatography (ERCP) rates. Compliance with and side effects of UDCA therapy were analyzed. RESULTS: A total of 751 patients were included in the study. Patients who had prior cholecystectomy or were lost to follow up were excluded. After exclusion criteria were applied, 461 patients were included for analysis: 303 in the UDCA group and 158 in the group who did not receive UDCA. Cholecystectomy rate was not significantly associated with UDCA administration, however there was a trend towards less cholecystectomy in patients who received UDCA (8.3% vs. 13.9%, p = 0.056). ERCP rate was significantly lower in patients who received UDCA (0.3% vs 2.5%, p = 0.031). Rate of gallstone disease requiring intervention, either cholecystectomy or ERCP, was significantly decreased in patients who received UDCA (8.9% vs 15.8%, p = 0.022). The most common barriers to compliance with UDCA were cost (45.4%) and nausea (18.1%). CONCLUSION: This is the first study to demonstrate lower rates of ERCP in patients receiving routine UDCA following LSG. Our findings support the ASMBS 2019 guidelines for administering UDCA after LSG for preventing gallstone disease.
引用
- Hossain I, Brodie J, O'Brien E, et al. Ursodeoxycholic acid for prevention of gallstone disease after laparoscopic sleeve gastrectomy: an Atlantic Canada perspective. Surg Endosc. 2023. PMID: 36952047. doi:10.1007/s00464-023-10015-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。